vs
Medpace Holdings, Inc.（MEDP）与Inotiv, Inc.（NOTV）财务数据对比。点击上方公司名可切换其他公司
Medpace Holdings, Inc.的季度营收约是Inotiv, Inc.的5.9倍（$708.5M vs $120.9M）。Medpace Holdings, Inc.净利率更高（19.1% vs -23.5%，领先42.6%）。Medpace Holdings, Inc.同比增速更快（32.0% vs 0.8%）。Medpace Holdings, Inc.自由现金流更多（$188.1M vs $-10.6M）。过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs 0.8%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
Inotiv公司是一家注册于美国印第安纳州的合同研究组织，总部位于该州拉斐特市。公司设有两大核心业务板块：发现与安全评估业务（DSA）以及研究模型与服务业务（RMS），可为小分子候选药物、生物治疗产品及生物医疗设备提供安全评估、分析、代谢研究、CMC及法规咨询等药物开发与环境科学相关服务。
MEDP vs NOTV — 直观对比
损益表 — Q4 2025 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $120.9M |
| 净利润 | $135.1M | $-28.4M |
| 毛利率 | — | — |
| 营业利润率 | 21.6% | -13.5% |
| 净利率 | 19.1% | -23.5% |
| 营收同比 | 32.0% | 0.8% |
| 净利润同比 | 15.5% | -2.7% |
| 每股收益（稀释后） | $4.65 | $-0.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $708.5M | $120.9M | ||
| Q3 25 | $659.9M | $138.1M | ||
| Q2 25 | $603.3M | $130.7M | ||
| Q1 25 | $558.6M | $124.3M | ||
| Q4 24 | $536.6M | $119.9M | ||
| Q3 24 | $533.3M | $130.4M | ||
| Q2 24 | $528.1M | $105.8M | ||
| Q1 24 | $511.0M | $119.0M |
| Q4 25 | $135.1M | $-28.4M | ||
| Q3 25 | $111.1M | $-8.6M | ||
| Q2 25 | $90.3M | $-17.6M | ||
| Q1 25 | $114.6M | $-14.9M | ||
| Q4 24 | $117.0M | $-27.6M | ||
| Q3 24 | $96.4M | $-18.9M | ||
| Q2 24 | $88.4M | $-26.1M | ||
| Q1 24 | $102.6M | $-48.1M |
| Q4 25 | 21.6% | -13.5% | ||
| Q3 25 | 21.5% | -4.9% | ||
| Q2 25 | 20.9% | -4.3% | ||
| Q1 25 | 20.3% | -2.4% | ||
| Q4 24 | 23.4% | -12.9% | ||
| Q3 24 | 21.1% | -10.1% | ||
| Q2 24 | 19.9% | -19.6% | ||
| Q1 24 | 20.4% | -36.2% |
| Q4 25 | 19.1% | -23.5% | ||
| Q3 25 | 16.8% | -6.2% | ||
| Q2 25 | 15.0% | -13.5% | ||
| Q1 25 | 20.5% | -12.0% | ||
| Q4 24 | 21.8% | -23.0% | ||
| Q3 24 | 18.1% | -14.5% | ||
| Q2 24 | 16.7% | -24.7% | ||
| Q1 24 | 20.1% | -40.4% |
| Q4 25 | $4.65 | $-0.83 | ||
| Q3 25 | $3.86 | $-0.14 | ||
| Q2 25 | $3.10 | $-0.51 | ||
| Q1 25 | $3.67 | $-0.44 | ||
| Q4 24 | $3.67 | $-1.02 | ||
| Q3 24 | $3.01 | $-0.73 | ||
| Q2 24 | $2.75 | $-1.00 | ||
| Q1 24 | $3.20 | $-1.86 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | $12.7M |
| 总债务越低越好 | — | $405.8M |
| 股东权益账面价值 | $459.1M | $109.0M |
| 总资产 | $2.0B | $734.3M |
| 负债/权益比越低杠杆越低 | — | 3.72× |
8季度趋势，按日历期对齐
| Q4 25 | $497.0M | $12.7M | ||
| Q3 25 | $285.4M | $21.7M | ||
| Q2 25 | $46.3M | $6.2M | ||
| Q1 25 | $441.4M | $19.3M | ||
| Q4 24 | $669.4M | $38.0M | ||
| Q3 24 | $656.9M | $21.4M | ||
| Q2 24 | $510.9M | $14.4M | ||
| Q1 24 | $407.0M | $32.7M |
| Q4 25 | — | $405.8M | ||
| Q3 25 | — | $402.1M | ||
| Q2 25 | — | $396.5M | ||
| Q1 25 | — | $399.5M | ||
| Q4 24 | — | $396.0M | ||
| Q3 24 | — | $393.3M | ||
| Q2 24 | — | $382.4M | ||
| Q1 24 | — | $380.6M |
| Q4 25 | $459.1M | $109.0M | ||
| Q3 25 | $293.6M | $136.0M | ||
| Q2 25 | $172.4M | $143.8M | ||
| Q1 25 | $593.6M | $157.7M | ||
| Q4 24 | $825.5M | $169.8M | ||
| Q3 24 | $881.4M | $170.5M | ||
| Q2 24 | $763.6M | $182.1M | ||
| Q1 24 | $671.5M | $207.2M |
| Q4 25 | $2.0B | $734.3M | ||
| Q3 25 | $1.8B | $771.1M | ||
| Q2 25 | $1.6B | $759.7M | ||
| Q1 25 | $1.9B | $766.0M | ||
| Q4 24 | $2.1B | $772.9M | ||
| Q3 24 | $2.1B | $781.4M | ||
| Q2 24 | $1.9B | $774.6M | ||
| Q1 24 | $1.8B | $815.4M |
| Q4 25 | — | 3.72× | ||
| Q3 25 | — | 2.96× | ||
| Q2 25 | — | 2.76× | ||
| Q1 25 | — | 2.53× | ||
| Q4 24 | — | 2.33× | ||
| Q3 24 | — | 2.31× | ||
| Q2 24 | — | 2.10× | ||
| Q1 24 | — | 1.84× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | $-5.4M |
| 自由现金流经营现金流 - 资本支出 | $188.1M | $-10.6M |
| 自由现金流率自由现金流/营收 | 26.6% | -8.8% |
| 资本支出强度资本支出/营收 | 0.6% | 4.3% |
| 现金转化率经营现金流/净利润 | 1.43× | — |
| 过去12个月自由现金流最近4个季度 | $681.9M | $-28.7M |
8季度趋势，按日历期对齐
| Q4 25 | $192.7M | $-5.4M | ||
| Q3 25 | $246.2M | $14.3M | ||
| Q2 25 | $148.5M | $-7.4M | ||
| Q1 25 | $125.8M | $-12.8M | ||
| Q4 24 | $190.7M | $-4.5M | ||
| Q3 24 | $149.1M | $-2.4M | ||
| Q2 24 | $116.4M | $-14.8M | ||
| Q1 24 | $152.7M | $16.9M |
| Q4 25 | $188.1M | $-10.6M | ||
| Q3 25 | $235.5M | $11.6M | ||
| Q2 25 | $142.4M | $-11.5M | ||
| Q1 25 | $115.8M | $-18.3M | ||
| Q4 24 | $183.0M | $-9.0M | ||
| Q3 24 | $138.5M | $-7.7M | ||
| Q2 24 | $103.5M | $-19.2M | ||
| Q1 24 | $147.2M | $9.9M |
| Q4 25 | 26.6% | -8.8% | ||
| Q3 25 | 35.7% | 8.4% | ||
| Q2 25 | 23.6% | -8.8% | ||
| Q1 25 | 20.7% | -14.7% | ||
| Q4 24 | 34.1% | -7.5% | ||
| Q3 24 | 26.0% | -5.9% | ||
| Q2 24 | 19.6% | -18.2% | ||
| Q1 24 | 28.8% | 8.3% |
| Q4 25 | 0.6% | 4.3% | ||
| Q3 25 | 1.6% | 1.9% | ||
| Q2 25 | 1.0% | 3.1% | ||
| Q1 25 | 1.8% | 4.4% | ||
| Q4 24 | 1.4% | 3.7% | ||
| Q3 24 | 2.0% | 4.1% | ||
| Q2 24 | 2.4% | 4.2% | ||
| Q1 24 | 1.1% | 5.9% |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 1.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
NOTV
| Research Models And Services Segment | $72.9M | 60% |
| Discovery And Safety Assessment Segment | $48.0M | 40% |
